Prions are infectious agents causing fatal neurodegenerative diseases of humans and animals. In humans, these have sporadic, acquired and inherited aetiologies. The inherited prion diseases are caused by one of over 30 coding mutations in the human prion protein (PrP) gene (PRNP) and many of these generate infectious prions as evidenced by their experimental transmissibility by inoculation to laboratory animals. However, some, and in particular an extensively studied type of Gerstmann-Str？ussler-Scheinker syndrome (GSS) caused by a PRNP A117V mutation, are thought not to generate infectious prions and instead constitute prion proteinopathies with a quite distinct pathogenetic mechanism. Multiple attempts to transmit A117V GSS have been unsuccessful and typical protease-resistant PrP (PrPSc), pathognomonic of prion disease, is not detected in brain. Pathogenesis is instead attributed to production of an aberrant topological form of PrP, C-terminal transmembrane PrP (CtmPrP). Barriers to transmission of prion strains from one species to another appear to relate to structural compatibility of PrP in host and inoculum and we have therefore produced transgenic mice expressing human 117V PrP. We found that brain tissue from GSS A117V patients did transmit disease to these mice and both the neuropathological features of prion disease and presence of PrPSc was demonstrated in the brains of recipient transgenic mice. This PrPSc rapidly degraded during laboratory analysis, suggesting that the difficulty in its detection in patients with GSS A117V could relate to post-mortem proteolysis. We conclude that GSS A117V is indeed a prion disease although the relative contributions of CtmPrP and prion propagation in neurodegeneration and their pathogenetic interaction remains to be established.
Collinge J, Clarke A (2007) A general model of prion strains and their pathogenicity. Science 318: 930–936. doi: 10.1126/science.1138718
[4]
Collinge J (2001) Prion diseases of humans and animals: their causes and molecular basis. Ann Rev Neurosci 24: 519–550.
[5]
Hill AF, Joiner S, Linehan J, Desbruslais M, Lantos PL, et al. (2000) Species barrier independent prion replication in apparently resistant species. Proc Natl Acad Sci USA 97: 10248–10253. doi: 10.1073/pnas.97.18.10248
[6]
Sandberg MK, Al Doujaily H, Sharps B, Clarke AR, Collinge J (2011) Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470: 540–542. doi: 10.1038/nature09768
[7]
Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, et al. (1998) A transmembrane from of the prion protein in neurodegenerative disease. Science 279: 827–834. doi: 10.1126/science.279.5352.827
[8]
Hegde RS, Tremblay P, Groth D, DeArmond S, Prusiner SB, et al. (1999) Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402: 822–826. doi: 10.1038/45574
[9]
Chakrabarti O, Hegde RS (2009) Functional depletion of mahogunin by cytosolically exposed prion protein contributes to neurodegeneration. Cell 137: 1136–1147. doi: 10.1016/j.cell.2009.03.042
[10]
Silvius D, Pitstick R, Ahn M, Meishery D, Oehler A, et al. (2013) Levels of the mahogunin ring finger 1 e3 ubiquitin ligase do not influence prion disease. PLoS ONE 8(1): e55575. doi: 10.1371/journal.pone.0055575
[11]
Mallucci GR, Campbell TA, Dickinson A, Beck J, Holt M, et al. (1999) Inherited prion disease with an alanine to valine mutation at codon 117 in the prion protein gene. Brain 122(Pt 10): 1823–1837. doi: 10.1093/brain/122.10.1823
[12]
Heston LL, Lowther DLW, Leventhal CM (1966) Alzheimer's disease. A family study. Arch Neurol 15: 225–233. doi: 10.1001/archneur.1966.00470150003001
[13]
Nochlin D, Sumi SM, Bird TD, Snow AD, Leventhal CM, et al. (1989) Familial dementia with PrP-positive amyloid plaques: a variant of Gerstmann-Straussler syndrome. Neurology 39: 910–918. doi: 10.1212/wnl.39.7.910
[14]
Hsiao KK, Cass C, Schellenberg GD, Bird TD, Devine-Gage E, et al. (1991) A prion protein variant in a family with the telencephalic form of Gerstmann-Straussler-Scheinker syndrome. Neurology 41: 681–684. doi: 10.1212/wnl.41.5.681
[15]
Bruce ME, Fraser H, McBride PA, Scott JR, Dickinson AG (1992) The basis of strain variation in scrapie. In: Prusiner SB, Collinge J, Powell J, Anderton B, editors. Prion Diseases in Human and Animals. London: Ellis Horwood.
[16]
Collinge J, Sidle KC, Meads J, Ironside J, Hill AF (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383: 685–690. doi: 10.1038/383685a0
[17]
Kovacs GG, Trabattoni G, Hainfellner JA, Ironside JW, Knight RS, et al. (2002) Mutations of the prion protein gene phenotypic spectrum. J Neurol 249: 1567–1582. doi: 10.1007/s00415-002-0896-9
[18]
Wadsworth JD, Collinge J (2007) Update on human prion disease. Biochimica et Biophysica Acta 1772: 598–609. doi: 10.1016/j.bbadis.2007.02.010
[19]
Hill AF, Joiner S, Beck J, Campbell TA, Dickinson A, et al. (2006) Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations. Brain 129: 676–685. doi: 10.1093/brain/awl013
[20]
Chapman J, Arlazoroff A, Goldfarb LG, Cervenakova L, Neufeld MY, et al. (1996) Fatal insomnia in a case of familial Creutzfeldt-Jakob disease with the codon 200Lys mutation. Neurology 46: 758–761. doi: 10.1212/wnl.46.3.758
[21]
Barbanti P, Fabbrini G, Salvatore M, Petraroli R, Cardone F, et al. (1996) Polymorphism at codon 129 or codon 219 of PRNP and clinical heterogeneity in a previously unreported family with Gerstmann- Straussler-Scheinker disease (PrP-P102L mutation). Neurology 47: 734–741. doi: 10.1212/wnl.47.3.734
[22]
Furukawa H, Doh-ura K, Kikuchi H, Tateishi J, Iwaki T (1998) A comparative study of abnormal prion protein isoforms between Gerstmann-Str？ussler-Scheinker syndrome and Creutzfeldt-Jakob disease. J Neurol Sciences 158: 71–75. doi: 10.1016/s0022-510x(98)00096-3
[23]
Piccardo P, Dlouhy SR, Lievens PMJ, Young K, Bird TD, et al. (1998) Phenotypic Variability of Gerstmann-Straussler-Scheinker Disease is Associated with Prion Protein Heterogeneity. J Neuropath Exp Neur 57: 979–988. doi: 10.1097/00005072-199810000-00010
[24]
Piccardo P, Liepnieks JJ, William A, Dlouhy SR, Farlow MR, et al. (2001) Prion proteins with different conformations accumulate in Geustmann-Straussler-Scheinker disease caused by A117V and F198S mutations. Am J Pathol 158: 2201–2207. doi: 10.1016/s0002-9440(10)64692-5
[25]
Parchi P, Chen SG, Brown P, Zou W, Capellari S, et al. (1998) Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Str？ussler-Scheinker disease. Proc Natl Acad Sci USA 95: 8322–8327. doi: 10.1073/pnas.95.14.8322
[26]
Tagliavini F, Lievens PMJ, Tranchant C, Warter JM, Mohr M, et al. (2001) A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Straussler-Scheinker disease A117V. J Biol Chem 276: 6009–6015. doi: 10.1074/jbc.m007062200
[27]
Wadsworth JD, Joiner S, Linehan J, Cooper S, Powell C, et al. (2006) Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain 129: 1557–1569. doi: 10.1093/brain/awl076
[28]
Piccardo P, Manson JC, King D, Ghetti B, Barron RM (2007) Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci USA 104: 4712–4717. doi: 10.1073/pnas.0609241104
[29]
Weissmann C, Flechsig E (2003) PrP knock-out and PrP transgenic mice in prion research. Br Med Bull 66: 43–60. doi: 10.1093/bmb/66.1.43
[30]
Weissmann C, Aguzzi A (2005) Approaches to therapy of prion diseases. Annu Rev Med 56: 321–344. doi: 10.1146/annurev.med.56.062404.172936
[31]
Collinge J, Palmer MS, Dryden AJ (1991) Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 337: 1441–1442. doi: 10.1016/0140-6736(91)93128-v
Scott M, Foster D, Mirenda C, Serban D, Coufal F, et al. (1989) Transgenic mice expressing hamster prion protein produce species- specific scrapie infectivity and amyloid plaques. Cell 59: 847–857. doi: 10.1016/0092-8674(89)90608-9
[34]
Collinge J, Palmer MS, Sidle KCL, Hill AF, Gowland I, et al. (1995) Unaltered susceptibility to BSE in transgenic mice expressing human prion protein. Nature 378: 779–783. doi: 10.1038/378779a0
[35]
Wadsworth JD, Joiner S, Linehan JM, Desbruslais M, Fox K, et al. (2008) Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proc Natl Acad Sci USA 105: 3885–3890. doi: 10.1073/pnas.0800190105
Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, et al. (1997) The same prion strain causes vCJD and BSE. Nature 389: 448–450. doi: 10.1038/38925
[38]
Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp H-P, et al. (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356: 577–582. doi: 10.1038/356577a0
[39]
Asante E, Linehan J, Desbruslais M, Joiner S, Gowland I, et al. (2002) BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J 21(23): 6358–6366. doi: 10.1093/emboj/cdf653
[40]
Wadsworth JD, Asante EA, Desbruslais M, Linehan J, Joiner S, et al. (2004) Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 306: 1793–1796. doi: 10.1126/science.1103932
[41]
Brown P, Gibbs CJ Jr, Rodgers Johnson P, Asher DM, Sulima MP, et al. (1994) Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 35: 513–529. doi: 10.1002/ana.410350504
[42]
Tateishi J, Kitamoto T, Hoque MZ, Furukawa H (1996) Experimental transmission of Creutzfeldt-Jakob disease and related diseases to rodents. Neurology 46: 532–537. doi: 10.1212/wnl.46.2.532
[43]
Race R, Raines A, Raymond GJ, Caughey B, Chesebro B (2001) Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: Analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans. J Virol 75: 10106–10112. doi: 10.1128/jvi.75.21.10106-10112.2001
Hsiao KK, Scott M, Foster D, Groth DF, DeArmond SJ, et al. (1990) Spontaneous neurodegeneration in transgenic mice with mutant prion protein. Science 250: 1587–1590. doi: 10.1126/science.1980379
[46]
Chiesa R, Piccardo P, Ghetti B, Harris DA (1998) Neurological illness in transgenic mice expressing a prion protein with an insertional mutation. Neuron 21: 1339–1351. doi: 10.1016/s0896-6273(00)80653-4
[47]
Wildegger G, Liemann S, Glockshuber R (1999) Extremely rapid folding of the C-terminal domain of the prion protein without kinetic intermediates. Nature Struct Biol 6: 550–553. doi: 10.1038/9323
[48]
Hart T, Hosszu LL, Trevitt CR, Jackson GS, Waltho JP, et al. (2009) Folding kinetics of the human prion protein probed by temperature jump. Proc Natl Acad Sci USA 106: 5651–5656. doi: 10.1073/pnas.0811457106
[49]
Nazor KE, Kuhn F, Seward T, Green M, Zwald D, et al. (2005) Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice. EMBO J 24: 2472–2480. doi: 10.1038/sj.emboj.7600717
[50]
Asante EA, Gowland I, Grimshaw A, Linehan JM, Smidak M, et al. (2009) Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. J Gen Virol 90: 546–558. doi: 10.1099/vir.0.007930-0
[51]
Wadsworth JD, Joiner S, Hill AF, Campbell TA, Desbruslais M, et al. (2001) Tissue distribution of protease resistant prion protein in variant CJD using a highly sensitive immuno-blotting assay. Lancet 358: 171–180. doi: 10.1016/s0140-6736(01)05403-4
[52]
Kascsak RJ, Rubenstein R, Merz PA, Tonna DeMasi M, Fersko R, et al. (1987) Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 61: 3688–3693.
[53]
Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, et al. (2003) Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 126: 1333–1346. doi: 10.1093/brain/awg125
